•Responsible for delivery of due diligence efforts supporting mergers and acquisitions and investments for private equity firms, Fortune 500 pharmaceutical and biotechnology companies•Conducting opportunity assessments to support new market entry, portfolio allocation decisions, and product development investment decisions

•Developed strategic platform addressing impact of coronavirus leading to the deployment of five telemedicine-focused tools for patients and health care providers

•Developed go-to-market strategy supporting $150M investment launching first specialty product in the US, including market landscape assessment, product positioning and messaging strategy, and commercial organization structure•Created a business plan supporting nationwide rollout of cutting-edge genomic sequencing system for one of the nation’s top 10 children’s hospitals, successfully supporting an investment of more than $30M from partnered hospitals

•Led creation of comprehensive launch plans and monitored execution for $400M launch for leading rare disease company, including creation and presentation to senior leadership of dashboards on progress against plan and risk and mitigation plans•Created model to forecast growth of pharmaceutical product to support negotiation with contract sales force vendor; model served as foundation for incentive compensation structure rolled out to more than 75 field representatives

• Performed analysis of treatment behaviors to determine relevant physician targets, identifying the optimal set of specialists to target as part of new product launch effort representing a $50m market• Designed and conducted market research study to discover insights into target market’s treatment paradigms, which resulted in a clear understanding of how to position a new therapy in the overall disease space• Collaborated with creative agencies to plan development schedule and content of marketing material• Delivered a comprehensive launch plan and timeline, including sales force training plan, multi-channel marketing mix, promotional material design plans, competitive analysis and budget

• Worked with investment banks on investor targeting and managed investor presentation materials on two separate financings totaling more than $55m that brought in seven new institutional biotechnology investors• Collaborated with senior management to prepare 6 quarterly presentations on full company update for Board of Directors, including business development progress, investor relations efforts, and clinical trial developments• Created and executed communication strategy for announcement of acquisition of a new asset as part of a strategic pivot resulting from a $26m licensing deal• Led drafting of new business plan, including market evaluation, competitor analysis, and estimated clinical trial requirements relating to strategic pivot including use of proceeds for $28m financing, which was filed as part of company’s 10-K• Supported business development team via license deal review and organizational support throughout negotiation resulting in a $48m development partnership• Initiated complete redesign of company materials, including corporate presentation and website as part of effort to modernize company’s marketing strategy for less than $10,000• Broadened company’s Investor Relations efforts by coordinating 12 investor conferences leading to one-on-one meetings with more than 200 institutional investors• Managed team of four summer interns to perform compensation and executive employment agreement analysis in an effort to improve company’s talent retention